What they found
A structure-based virtual screen of >11,000 compounds against the α-synuclein fibril structure identified IP-045 (2-fluorophenyl 3-(1H-indol-3-yl)propanoate) as a lead chemical chaperone. IP-045 strongly inhibited α-synuclein aggregation in vitro, reduced ROS and ER stress markers in cell models, and improved motor/cognitive performance in a rotenone-induced PD rat model. The compound is an indole derivative — notably, indole-3-acetic acid is one of our pharmacochaperone lead compounds.
Lateral connection
The virtual screening pipeline (11K compounds → 4 candidates → lead optimization → in vivo) parallels our STRC pharmacochaperone campaign, which has completed phases 0-3 with a top-5 leads shortlist including an indole-3-acetic acid derivative. IP-045 is structurally related (indol-3-yl propanoate vs. indole-3-acetic acid). Their demonstration that an indole-class chaperone works in vivo for protein misfolding provides confidence in our indole lead chemotype.
Hypothesis suggested
Indole-scaffold chemical chaperones may have broad utility for rescuing protein misfolding/aggregation. Our indole-3-acetic acid lead for STRC E1659A is from the same chemical family. Maps to STRC Pharmacochaperone Virtual Screen E1659A (S-tier). Testable: does IP-045 itself show any STRC E1659A binding activity?
What could be computed
Pharmacophore comparison between IP-045 and our indole-3-acetic acid lead. Dock IP-045 against STRC E1659A binding pocket. SAR analysis of the indole scaffold — which substituents drive chaperone vs. aggregation-inhibition activity?
Links
Connections
[part-of]h01 hub[source]auto-indexed 2026-04-21 by strc-lit-watch